The elevated P/S ratio suggests that the market is pricing the company as a binary outcome play rather than a traditional operating entity. Investors should monitor whether this valuation can be sustained as the company transitions into more capital-intensive pivotal trials, which may necessitate further equity dilution.

The persistent negative operating margins underscore the heavy reliance on R&D spending to drive clinical milestones. Until the company achieves regulatory approval and transitions to high-volume automated manufacturing, profitability will likely remain elusive and highly sensitive to the timing of clinical trial expenditures.

The extreme volatility in the cash conversion cycle suggests that management is struggling to balance the procurement of specialized materials with the unpredictable timing of clinical trial requirements. This lack of operational rhythm warrants further investigation into the company's supply chain resilience and vendor relationships.

While the current ratio suggests a strong short-term buffer, the rapid depletion of cash through high R&D burn rates implies that this liquidity is transient. Investors should monitor the cash-to-burn ratio closely, as the company's ability to fund operations without further dilution remains a critical risk.